Maturation of primary RNA transcripts of eukaryotic genes often involves the removal of introns and joining of exons. The fidelity of RNA splicing is dependent on the identity of the nucleotide (nt) sequences at exon/intron boundaries. Most importantly, the highly conserved intronic 5 GT and 3 AG sequences are essential for correct splicing. Substitution of GT by any other nt leads to incomplete mRNA and a disruption of protein structure. We describe here the results of our transfection experiments in COS-1 cells with a CYP21 genomic construct that contained an IVS 2+1G<A mutation. Analysis of the transcripts by RT-PCR revealed that two different transcripts were generated by this mutant genome. In all the splicing products, we found that the entire exon 2 was deleted. Surprisingly, 30% of the transcripts from this mutant CYP21 genome were accompanied by an inclusion of 3 intron 2 sequences due to the use of a different splice acceptor site. This is the first report of the molecular characterization of a splice donor site mutation in CYP21 via transcription in COS-1 cells.
Introduction
Congenital adrenal hyperplasia (CAH, OMIM 201910 ) is one of the most common inborn errors of metabolism. More than 90% of CAH cases are caused by mutations of the gene which encodes steroid 21-hydroxylase (P450c21, CYP21) on human chromosome 6p21·3. Deficiency of steroid 21-hydroxylase prevents the conversion of 17-hydroxyprogesterone to 11-deoxycorticosterone, leading to the abolition of the synthesis of cortisol/aldosterone and the overproduction of androgen.
To date, 56 mutations in the CYP21 gene have been reported (Krawczak & Cooper 2000 , Lee 2001 ). Fifteen of these mutations are 'gene conversion mutations' due to intergenic recombination of DNA sequences between CYP21 and the CYP21P pseudogene (Lee 2001) . The other 41 mutations described are not present in the pseudogene, and are likely to be spontaneous mutations. Dysfunctional protein with mutated functional domains due to different missense mutations has been reported. Mutations occur at the membrane association region (Picado-Leonard & Miller 1988 , Hu et al. 1996 , Lajic et al. 1999 , the substrate-binding site (Picado-Leonard & Miller 1988) , and the heme-binding site (Chiou et al. 1990 , Nikoshkov et al. 1998 . Obviously, mutations in these regions have a deleterious effect on enzyme activity.
Gene deletions or insertions of CYP21 (Lee 2001) , including complete gene deletion or the common 707 del8 mutation, always lead to a complete loss of enzyme activity. Finally, a common 655A/C<G mutation within intron 2 has been reported in CAH patients (Higashi et al. 1988) . S1 mapping and COS-7 cells transfection experiments have revealed that this mutation causes the introduction of an upstream acceptor site resulting in the synthesis of a truncated or an abnormal protein (Higashi et al. 1988) . In addition, transversion mutations at the splicing junction in intron 1 and intron 7 of the CYP21 gene have been reported in CAH patients (Wedell & Luthman 1993 , Lajic & Wedell 1996 . The AG to GG mutation at the splicing acceptor site in intron 1 (Lajic & Wedell 1996) and the GT to CT mutation at the donor site in intron 7 (Wedell & Luthman 1993) both disrupt the canonical consensus sequences which are crucial for splicing processing. However, the effect on the splicing process caused by these mutations in the CYP21 gene has not been further studied.
In this study, we provide evidence to explain the consequence of the IVS 2+1G<A mutation in the CYP21 gene found in two CAH patients. Amplification of the mutant CYP21 gene directly from the CAH patient in combination with transfection of COS-1 cells has enabled us to analyze the genetic defects in the splicing process in vitro.
Materials and Methods

Subjects
The two CAH patients found to carry the IVS 2+1G<A mutation on one of the chromosomes were described previously (Lee et al. 1998) .
Mutated CYP21 gene amplification and construction of expression plasmid
Genomic DNA from one of the CAH patients carrying the IVS 2+1G<A mutation was directly amplified by differential amplification with allele-specific primers (BF1 and 21BR, Table 1) as previously described (Lee et al. 1996 , Lee 2001 (Higashi et al. 1986 ). After complete digestion of the 2·8 kb PCR fragments with BamHI and XhoI, the digested fragment was separated on 1·5% agarose gel and purified. The purified DNA (Fig. 1a , lane 1) was cloned into the 5·4 kb pcDNA3 mammalian expression vector (Invitrogen Corporation, Carlsbad, CA, USA). After restriction map analysis (data not shown) and DNA sequencing (Fig. 1c) , a clone containing the mutant CYP21gene (Fig. 1a , lane 2) was obtained. A vector containing the normal CYP21 gene was also constructed. All the constructs were sequenced to confirm their identity.
Transfection of COS-1 cells with recombinant pcDNA3 plasmid containing either normal or mutated CYP21 gene
The CsCl gradient-banded pcDNA3 constructs with mutated CYP21 or the normal CYP21 gene were individually transfected into COS-1 cells using Lipofectamine Plus Reagent (Life Technologies, Grand Island, NY, USA). After 3 days incubation in Dulbecco's modified Eagle's medium containing 15% fetal bovine serum, the COS-1 cells were harvested and total cellular RNA was purified using Trizol reagent (Life Technologies). The purity and the amount of RNA prepared were determined by the reading at OD 268/280 in a GeneQuant II RNA/ DNA calculator (Amersham Pharmacia Biotech Inc., Piscataway, NY, USA). Total RNA from transfected COS-1 cells was subjected to RT-PCR amplification using primers E1/E3 (Table 1) .
Analysis of RT-PCR product
After RT-PCR amplification, the PCR products were further subcloned into the pGEM-T vector system (Promega Corporation, Madison, WI, USA) following the manufacturer's instructions. After transformation, the colonies were screened by PCR amplification with the Splice donor site mutation in CYP21 · H-H LEE and S-F CHANG 399 primers cdn62-5 /C4 (Table 1 ). The PCR product was electrophoresed in 1·5% agarose gel to check the DNA product.
DNA sequencing
Basically, the PCR product amplified from the clones identified was directly used as a template for DNA sequencing. The reaction mixture of the ABI PRISM Dye Termination Cycle Sequencing Kit (Perkin-Elmer, Foster City, CA, USA) was applied to the DNA cycling reaction. The protocol was used as described previously (Lee et al. 1998) .
Results
Expression of mutated gene in COS-1 cells
To analyze the effect of splicing site mutation on RNA processing, the transcription of these constructed plasmids was analyzed in COS-1 cells 72 h after transient transfection. Total RNA from transfected cells was subject to RT-PCR amplification using primers E1/E3 (Table 1) . One single 296 bp band (Fig. 1b, lane 1) was present in RT-PCR products of RNA from cells transfected with plasmid containing the normal CYP21 gene, indicating the correct RNA processing. A small amount of 683 bp band of DNA contaminant was also observed whose size corresponded to the predicted PCR product from the genome template. However, there were two RT-PCR products of RNA from cells transfected with mutant CYP21 plasmid (Fig. 1b , lane 2) and both were smaller than the one that amplified from the normal CYP21 RNA (Fig. 1b, lane 1) .
Sequencing analysis of the alternation of RNA splicing in mutant CYP21 gene
To analyze the transcript of RNA splicing of the mutant CYP21 gene, the RT-PCR product was further subcloned into the pGEM-T vector. The colony obtained was subject to PCR amplification using primers cdn62-5 /C4 (Table 1 ) and sequencing analysis. Two different inserts of 134 and 153 bp sizes were found (Fig. 1b, lanes 3 and 4) . These two fragments were smaller than the transcript product of the normal CYP21 gene (224 bp, Fig. 1b, lane  5) . From sequencing analysis, it appeared that the 134 bp fragment lacked the entire introns 1, 2 and exon 2 (Fig.  2a) , whereas the 153 bp fragment had a deletion of intron 1, entire exon 2 and part of intron 2. In other words, the 153 bp fragment had sequences connecting exon 1 directly to the last 19 nucleotides (nts) of intron 2 (Fig. 2b) . There was no other transcript product found in RT-PCR products of RNA from the mutant CYP21 gene.
Observation of the frequency of splicing in mutant CYP21 gene in vitro
To measure the frequency of preferential sites used for RNA splicing in the mutant CYP21 gene, 99 transformed colonies were sequenced to identify the splicing sites.
Results showed that there were 71 clones containing the 134 bp fragment lacking the entire exon 2 (70·7%) and 29 clones (29·2%) that had the 153 bp product produced from the splicing event that connected exon 1 to the last 19 nts of intron 2 (Table 2) .
Discussion
Using differential PCR (Lee et al. 1996 , Lee 2001 combined with single-strand conformation polymorphism analysis (Lee et al. 1998) , we characterized the transcription pattern of the splicing donor site mutated CYP21 gene with GT changed to AT in intron 2 (Fig. 3a) . This CYP21 mutation was found in one of the chromosomes of two CAH patients we have screened before (Lee et al. 1998) . Both patients showed salt-wasting and exhibited a picture of clitoromegaly after birth (Lee et al. 1998) . We had speculated that this splicing site mutation might either lead to skipping of exon 2, or result in the use of cryptic splice donor sites creating a premature TAA stop codon located at nts 46-48 of the intron 2 based on sequence prediction (Lee et al. 1998 ). In the case of an alternative usage of a cryptic donor site this would result in the formation of a truncated, unstable protein with no enzymatic activity. However, no sequences resembling the consensus splice donor site are present within intron 2. To find out the real effect of this mutation, transfection studies of mutant CYP21 gene into COS-1 cells were carried out, followed by RT-PCR analysis of the resulting mRNA (Fig. 1) . To our surprise, our experiments revealed the formation of two types of transcripts from this mutant CYP21 gene. Type I transcript lacked the entire exon 2 as expected. However, the second transcript (type II) also lost exon 2 but contained an insertion of the last 19 nt of intron 2 between exons 1 and 3 (Figs 2 and 3 ). Our data show that the IVS 2+1G<A mutation completely inhibits the use of this splice donor site. This result emphasizes the requirement of the invariability of GT dinucleotides at the 5 splicing sites for correct RNA processing. The effect of such a mutation may differ from gene to gene. In vertebrates, exon skipping at the 5 splicing site was found in at least 18 naturally occurring mutations (Talerico & Berget 1990) . However, transcripts resulting from exon skipping are only a minor splice variant in o -thalassemia in humans, in which the main product results from the use of a downstream splice donor within the following intron (Chen et al. 1989) . Furthermore, in the human chorionic somatomammotropin-like gene (Wieringa et al. 1983 ) and the rabbit -globin gene (Treisman et al. 1982) resulting from splice donor mutations, exon skipping does not occur at all. In both cases, a cryptic splice site within the preceding exon was used.
We report in this study that the type I transcript lacking exon 2 is the predominant splicing product, proving that exon skipping is the most important result of the IVS 2+1G<A mutation. However, the less common type II transcript still constituted approximately one-third of the mRNAs produced (Table 2) , making it more than a rare splice variant. In this transcript, skipping of exon 2 is found together with an insertion of the last 19 nts of intron 2, due to the use of a cryptic splice acceptor site downstream from exon 3. This result indicates that mutation of a splice donor site may not only influence the use of the donor site itself, but also influences the use of the downstream splice acceptor site. Although, the molecular basis of this preference is still unclear, our study once more emphasizes that it is impossible to predict the effects of splice mutations on mRNA formation, and that they can only be revealed by in vitro or in vivo studies.
Four splicing site mutations in the CYP21 gene have been reported so far (Higashi et al. 1988 , Wedell & Luthman 1993 , Lajic & Wedell 1996 , Lee et al. 1998 . The effect for only one of these mutations (656 A/C<G) was proven from mRNA studies (Higashi et al. 1988) . By way of differential amplification of the CYP21 gene, we have established a reliable method to analyze the effect of mutations occurring at either splicing donor or acceptor sites of the CYP21 gene. 
